FIGURE 3 Effect of combinations of ACCi with PPAR/THRβ agonists on liver and circulating TG in dyslipidemic rats. (A) Longitudinal circulating TG with PPAR/THRβ agonists treated as monotherapy (shaded area) or in combination with ACCi. (B) Circulating TG on Day 22 of FFD feeding, 2 weeks after initiation of PPAR agonist treatment and 1 week after initiation of ACCi treatment ( n  = 5–10/group). (C) Terminal liver TG, collected in the fed state, 8 h after dose. Data were generated across three independent studies as described in Table  S1 , and circulating TG were measured in serum (Study 2) and plasma (Studies 3–4). Data are presented as mean ± SEM ( n  = 8–10 animals/ group); * p  ≤ 0.05, ** p  ≤ 0.01, *** p  ≤ 0.001, **** p  ≤ 0.0001 versus vehicle;  † 
 p  ≤ 0.05,  †† 
 p  ≤ 0.01,  ††† 
 p  ≤ 0.001,  †††† 
 p  ≤ 0.0001 versus ACCi monotherapy, or as indicated.